Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity	
CHEMGENEX PHARMACEUTICALS LTD	

ABN 79 000 248 304

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- ⁺Class of ⁺securities issued or to be issued EXPIRY OF UNLISTED ESOP OPTIONS.
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

(CXSAI) ESOP OPTIONS WITH A RANGE OF EXERCISE PRICES LAPSED ON 15 JUNE 2010.

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally respects from the date of allowith an existing *class of control of the additional securities of the additional securities of the additional securities of the additional securities of the date from which they do the extent to which participate for the next diversity (in the case of a distribution) or interest pay the extent to which they can always and the extent to which they can always are additionally of the extent to the next diversity distribution or interest payor.	otment quoted do not they ridend, trust, ment do not an in ridend,	N/A	
5	Issue price or consideration		N/A	
6	Purpose of the issue (If issued as consideration for acquisition of assets, clearly in those assets)		LAPSING OF	UNLISTED ESOP OPTIONS.
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	N/A		
		NT 1		1+01
8	Number and *class of all *securities quoted on ASX (including the securities in clause 2 if applicable)		9,328	+Class ORD SHARES OPTIONS EXPIRING 8 FEB 2012, EXERCISABLE AT \$0.68
9	Number and +class of all +securities not quoted on ASX (<i>including</i> the securities in clause 2 if applicable)	Numb 20,55	per 1,000	+Class ESOP AND AGM APPROVED OPTIONS EXPIRING AT VARIOUS
				DATES AND EXERCISABLE AT VARIOUS PRICES
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A		

Part 2 - Bonus issue or pro rata issue

11	Is se require	ecurity holder approval d?	N/A
12	Is the renound	issue renounceable or non-ceable?	N/A
13	Ratio is	n which the ⁺ securities will red	N/A
14	+Class offer re	of *securities to which the	N/A
15	⁺ Record entitlen		N/A
16	(or sub	oldings on different registers bregisters) be aggregated for ting entitlements?	N/A
17		for deciding entitlements in to fractions	N/A
18	entity will r docume	ents curity holders must be told how their	N/A
		ts are to be dealt with. rence: rule 7.7.	
	Closs icici	rence. rule 7.7.	
19	Closing accepta	g date for receipt of inces or renunciations	N/A
	20	Names of any underwriters	N/A
	21	Amount of any underwriting commission	g fee or N/A
	22	Names of any brokers to the	issue N/A
	23	Fee or commission payable broker to the issue	e to the N/A

⁺ See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do ⁺ security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do ⁺ security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Despatch date	N/A
	t 3 – Quotation d only complete this section if you are appl	
34	Type of securities (tick one)	
(a)	Securities described in Part 1	
(b)		of the escrowed period, partly paid securities that become fully paid, employee nds, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities Tick to indicate you are providing the information or N/A documents 35 If the +securities are +equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders If the +securities are +equity securities, a distribution schedule of the additional 36 +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37 A copy of any trust deed for the additional *securities Entities that have ticked box 34(b) 38 Number of securities for which ⁺quotation is sought 39 Class of *securities for which quotation is sought 40 Do the *securities rank equally in all respects from the date of allotment with an existing +class of quoted *securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)

⁺ See chapter 19 for defined terms.

Number and *class of all *securities quoted on ASX (including the securities in clause 38)

Number	+Class

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date: 15 June 2010

Print name: James Campbell, Company Secretary

== == == ==